Pregabalin
Product Images NDC 50090-5177

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905177)

Pregabalin 75 mg capsules label from A-S Medication Solutions. The label displays the product name Pregabalin, strength of 75 mg per capsule, and packaging details with a quantity of 90 capsules. It includes storage instructions to keep the product between 68 to 77 degrees Fahrenheit and features a QR code along with lot and product numbers.*

FDA Label Image

Figure 1 (Pregabalincaps Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at different doses (200 mg, 100 mg, 25 mg three times a day) and placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline, illustrating comparative efficacy across dosages and placebo.*

FDA Label Image

Figure 2 (Pregabalincaps Fig02)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Two lines compare Pregabalin 100 mg three times a day and placebo, illustrating patient responses over increasing pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalincaps Fig03)

A line chart depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain, with each dose group represented by distinct lines.*

FDA Label Image

Figure 4 (Pregabalincaps Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating the relative effectiveness in pain improvement.*

FDA Label Image

Figure 5 (Pregabalincaps Fig05)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with vertical lines marking percent improvement levels at 30% and 50%.*

FDA Label Image

Figure 6 (Pregabalincaps Fig06)

A bar chart comparing responder rates (%) in two clinical studies labeled Study E1 and Study E3. Study E1 shows response rates across placebo and four doses of a drug given twice daily (BID), ranging from 50 mg to 600 mg. Study E3 compares placebo to 600 mg given twice daily (BID) or three times daily (TID). The chart includes sample sizes (N) below each group and notes statistical significance versus placebo.*

FDA Label Image

Figure 7 (Pregabalincaps Fig07)

A line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day for pregabalin from four different studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The graph displays significant p-values at various doses, illustrating dose-dependent seizure reduction compared to placebo.*

FDA Label Image

Figure 8 (Pregabalincaps Fig08)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. The chart compares Pregabalin at daily doses of 300 mg, 450 mg, and 800 mg against a placebo, showing patient response distributions across improvement percentages from 0 to 100%.*

FDA Label Image

Figure 9 (Pregabalincaps Fig09)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR over 180 days for Pregabalin and Placebo groups. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, with Pregabalin showing a consistently higher percentage than Placebo across the study period.*

FDA Label Image

Figure 11 (Pregabalincaps Fig10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12 for Pregabalin versus Placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100. Solid line represents Pregabalin and dashed line represents Placebo, with Pregabalin showing a higher percent of subjects improved at most thresholds.*

FDA Label Image

Figure 12 (Pregabalincaps Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo over a range of percentage improvement from baseline to Week 16 BOCF. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100 percent. Pregabalin shows higher improvement rates compared to Placebo throughout the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalincaps Formula)

An illustrated formula showing the calculation for creatinine clearance (CLcr). The formula is (140 minus age in years) multiplied by weight in kilograms, divided by (72 multiplied by serum creatinine in mg/dL), with a note to multiply by 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalincaps Str)

Chemical structure diagram of Pregabalin showing its molecular configuration with carboxyl (CO2H) and amino (NH2) functional groups highlighted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.